Clin2
NCT06759701Possibly a fitRecruiting

Weight loss drug before prostate cancer surgery pilot study

DiabetesProstate Cancer

Treatments studied

Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.

This study tests if taking tirzepatide (a weight loss medicine) before prostate removal surgery is safe and helpful for overweight men with intermediate-risk prostate cancer. It aims to see if losing weight can improve surgery outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
30 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are a man between 30 and 75 years old
  • You have been diagnosed with prostate cancer that is intermediate-risk and has not spread
  • You are planning to have surgery to remove your prostate
  • You have diabetes and are overweight (BMI 27 or higher, or waist over 40 inches) OR you have a BMI of 30 or higher, OR a BMI of 27 or higher with a weight-related condition (like high blood pressure, high cholesterol, sleep apnea, or heart disease)
  • You have not taken weight loss medicine, had weight loss surgery, or lost more than 11 pounds in the last 3 months
  • You do not have severe kidney, liver, pancreas, stomach, or psychiatric conditions

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07727473Not yet recruiting· Early Phase 1
Semaglutide before prostate removal for eligible men

This trial tests whether taking semaglutide before prostate removal surgery can help men with intermediate-risk prostate cancer and high BMI. The treatment is given for 3-6 months before surgery.

Gilbert, Arizona
NCT06518837Recruiting· Phase 2
Tirzepatide for weight loss in early breast cancer

This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.

Elizabeth, New Jersey
NCT07065552Recruiting· Early Phase 1
Tirzepatide for weight-linked endometrial cancer

This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.

Chapel Hill, North Carolina
NCT06721507Recruiting· Phase 4
Tirzepatide after weight loss surgery

This study tests whether giving tirzepatide (a medicine that helps with weight and blood sugar) right after weight loss surgery can improve results. It is for people who are already scheduled for sleeve gastrectomy or gastric bypass at UK HealthCare.

Lexington, Kentucky
NCT06751589Recruiting· Early Phase 1
Weight loss drug study for people with endometrial cancer

This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.

Basking Ridge, New Jersey
NCT07096908Recruiting· Phase 4
Tirzepatide for weight loss in type 1 diabetes

This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.

Kuwait City, Sharq

Hear when a new Diabetes trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.